Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2018

View Archived Issues

PI3Kdelta in autoimmunity

Ketamine activates opioid system

Repeat expansions disrupt large-scale genome organization

HECTD3 negatively regulates host defense against intracellular bacteria by modulation of type I IFN

Complete response observed in phase I study of ET-140202 in metastatic HCC

Brain immune cells show multiple sex differences

TSI initiates phase II study of its novel treatment regimen for ischemic stroke

Yumanity Therapeutics names first clinical candidate for Parkinson's disease

MabSpace initiates Chinese phase I trial of MSB-2311, files IND for MSB-0254

C11orf95-RELA fusion drives ST-ependymoma formation through NF-kappaB and other signaling pathways

Beta1-integrin promotes endothelial barrier disruption: a new target to prevent vascular leakage

HAS2 gene linked to the pathogenesis of lower extremity varicose veins

Combining ACE2 and BNP biomarkers improves risk stratification in patients with aortic stenosis

Researchers identify FHOD3 as a novel disease-causing gene in hypertrophic cardiomyopathy

Torrent Pharmaceuticals patents compounds for asthma and COPD

A*STAR identifies new SMYD3 inhibitors for cancer

Xenon Pharmaceuticals to develop ezogabine for KCNQ2 epileptic encephalopathy

Chinese researchers disclose Abeta aggregation inhibitors

FDA approves Tiglutik oral suspension for the treatment of ALS

Phase IIa study of Yeliva for cholangiocarcinoma advances to second stage

Eli Lilly presents AOC3 inhibitors

Luye initiates phase III trials in China with LY-01005 for prostate cancer

Atara Biotherapeutics to develop CAR T immunotherapies with Moffitt Cancer Center

NIH grants supports Hepseros' development of human-on-a-chip technology

Soleno amends phase III trial protocol for diazoxide choline in Prader-Willi syndrome

Checkpoint Therapeutics reports promising phase I/II data with CK-101 in EGFR-mutated NSCLC

Compugen initiates clinical testing of COM-701 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...